Form 4: Immunome Director Boosts Stake with 5,000 Share Purchase

Immunome Inc. Director Jean Jacques Bienaime acquired 5,000 shares of the company's common stock at a weighted average price of $9.38 per share on June 3, 2025, increasing his direct beneficial ownership to 36,415 shares.

Summary

• Immunome Inc. (IMNM) Director Jean Jacques Bienaime purchased 5,000 shares of common stock.
• The transaction occurred on June 3, 2025.
• The shares were acquired at a weighted average price of $9.38 per share, with prices ranging from $9.36 to $9.40.
• Following this transaction, Mr. Bienaime directly beneficially owns 36,415 shares of Immunome common stock.
• The transaction was made pursuant to a Rule 10b5-1 trading plan.

Sentiment

Score: 7

Explanation: The sentiment is positive because a director's purchase of company stock typically indicates confidence in the company's future prospects and valuation, which is generally viewed favorably by investors.

Positives

• A director's purchase of company stock often signals confidence in the company's future prospects and valuation.
• The transaction was executed under a Rule 10b5-1 plan, indicating a pre-planned acquisition strategy.

Future Outlook

This Form 4 filing does not provide specific forward-looking statements or guidance regarding the company's future performance or outlook. It solely reports an insider transaction.

Industry Context

Insider buying, such as this director's purchase, is generally viewed by the market as a positive signal, suggesting that those with intimate knowledge of the company believe its stock is undervalued or that positive developments are anticipated. This can be particularly impactful in the biotechnology sector where company-specific news often drives stock performance.

Comparison to Industry Standards

• Insider purchases are a common occurrence across all industries, including biotechnology. While there isn't a direct 'industry standard' for the volume or frequency of insider buying, significant purchases by key executives or directors are often interpreted as a strong vote of confidence.
• For example, similar insider purchases have been observed in other biotech companies like Moderna (MRNA) or BioNTech (BNTX) where executives or board members have increased their holdings, often preceding periods of positive clinical trial results or regulatory approvals.

Stakeholder Impact

• Shareholders: May view the director's purchase as a positive signal, potentially increasing confidence in the company's stock and future performance.

Key Dates

Keywords

Immunome, IMNM, insider trading, Form 4, stock purchase, director, common stock, beneficial ownership, Jean Jacques Bienaime